Dr. Dominik Kugelstadt joins Rentschler Biopharma as Head of Clinical and Commercial Manufacturing, Laupheim

Laupheim, Germany, July 12, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Dr. Dominik Kugelstadt as Head of Clinical and Commercial Manufacturing, Laupheim, effective July 1, 2023. In this position, Dr. Kugelstadt is responsible for all areas of production and reports to Laupheim’s Site Head as a member of the Laupheim Site Leadership Team. With his extensive experience in the manufacture of complex biologics and comprehensive knowledge of production management, Dr. Kugelstadt will play a leading role in ensuring the quality of Rentschler Biopharma’s service offering and expanding its portfolio.

“I am very pleased to welcome Dominik to our team,” said Christiane Bardroff, COO of Rentschler Biopharma. “As an experienced manufacturing executive, he knows our core business well and brings impressively broad expertise in production, that he will apply in leading our manufacturing department in Laupheim. He shares our focus on quality and will leverage his multifaceted profile and expertise to play a key role in continuing to sustainably create value for our clients.”

Dominik Kugelstadt, Head of Clinical and Commercial Manufacturing, Laupheim, added: “The combination of tradition and sustainability, along with the diversity of its projects, make Rentschler Biopharma a truly attractive place to work. I look forward, along with our talented and motivated team, to bringing solutions to existing and new clients, as we work together to bring novel biopharmaceuticals to help or even cure patients with serious and life-threatening diseases.”

Dr. Kugelstadt has more than 13 years of management experience in biopharmaceutical manufacturing. Before joining Rentschler Biopharma, he worked at Sanofi. Most recently, he was Head of Sanofi's Mammalian Launch Plant, a manufacturing facility focused on the production of antibodies for Phase III clinical development and commercial launch. In this role, he was responsible for all aspects of production, including operational manufacturing, infrastructure, validation, supply chain and plant expansion, as well as audits and representing the company to regulatory authorities and other stakeholders. Prior to Sanofi, he worked for several years at Genzyme Virotech (later Sekisui Virotech). Dr. Kugelstadt received his Ph.D. from the Institute of Infectious Diseases at the University Hospital of Heidelberg (Ruprecht Karls University Heidelberg) and the Johannes Gutenberg University Mainz where he also graduated in biology.

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. Rentschler ATMP Ltd., located in Stevenage, UK, is dedicated to cell and gene therapies.

For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.